Interview with Leo Van Der Geer, President & CEO, Solvay Italy
You have led a successful career within the Solvay Group in various European countries. Looking back at all these…
Solvay Italy
Last updated: 13.02.2014
Address: Via Della Liberta, 30, 10095 Grugliasco (TO),Italy
Tel: +39 011 4027911
Web: http://www.solvay.it/IT/Home.aspx
Company description
The first Solvay plant was built in 1912 in Rosignano, near Livorno, and the group now has 13 production plantsin Italy, and is active in the chemical, pharmaceutical and plastics fields, with annual sales up to 1034 million and investments of around 107 million euro in 2007. It now employs about 2,800 people.Solvay is now looking at different therapeutic areas in order to comfort its growth and prevent drawbacks from products falling into the public domain; orphan diseases being one of the most important.
Products and services
Interviews
Related
Italy / Market Access Reform: A Watershed Moment?
In recent months, a profound transformation has been occurring right at the core of the Italian pharmaceutical…
Italy / Mandatory COVID-19 Vaccines for Healthcare Workers; Chiesi & Angelini’s AI Investments; Sputnik V Manufacturing
The latest Italy Pharma News, including the government’s decision to make COVID-19 vaccines mandatory for all…
Italy / Stevanato’s $5 bn valuation; Zolgensma Approval; Sputnik V Manufacturing
The latest from Italian pharma, including the foreign minister’s plea for delivering on COVID-19 vaccine…
Italy / Menarini CEO on Averting Future Health Crises; Alfasigma Hackathon; January COVID Vaccines
A roundup of some of the most important recent stories from Italian pharma, including an in-depth interview with…
Pricing / Italy Takes Global Transparency Lead by Forcing Pharma to Disclose Public R&D Funding
In July 2020, Italy became the first country in the world to mandate pharma companies to disclose data surrounding…
News Roundup / Italy Pharma July 2020
Below we present recent news from Italy’s biopharma industry, including the recent acquisition of Stemline…
M&A / Menarini Makes Big US Oncology Move with Stemline Acquisition
Menarini Group, the largest Italian pharmaceutical company by turnover, has made its first move into the US…
Internationalization / Chiesi Moves into Rare Diseases & the US Market
Italian mid-cap firm Chiesi is continuing its expansion in the USA market with the launch of a Boston-based…
Interview: Luca G. Guidotti – Deputy Scientific Director, San Raffaele…
Prof. Luca G. Guidotti discusses the esteemed positioning of San Raffaele within the global scientific community,…
Interview: Gianvito Martino – Scientific Director & Director of the…
The division of neuroscience at the San Raffaele Scientific Institute is one of the best worldwide performers in…
Interview: Angelo Corti – Director, Division of Experimental Oncology, San…
Professor Angelo Corti, Director of the Experimental Oncology division of the SRSI, discusses approaches to…
Interview: Paola Pozzi – Head, Office of Biotechnology Transfer, San…
Dr. Paola Pozzi, the head of the Office of Biotechnology Transfer at the San Raffaele Scientific Institute,…
